IL3RA and leukemia: Additionally, in this animal model, CAR.CD123-NK cells were able to significantly control leukaemia progression compared to NT-NK cells in the control mouse cohort (Fig. 7A and Additional file 1: Fig. S7B), translating into a significantly prolonged OS of the mice (median OS of 31 days for mice treated with NT-NK cells, range 31–38; OS timing undefined for mice receiving CAR.CD123-NK cells; p = 0.009; Fig. 6B).